Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Fineline Cube Apr 1, 2026
Company

Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025

Fineline Cube Apr 30, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1...

Company Deals

Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China

Fineline Cube Apr 30, 2025

France-based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the signing of a cooperation agreement with...

Company

Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands

Fineline Cube Apr 30, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) released its Q1 2025 financial report, showing net sales...

Company

Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware

Fineline Cube Apr 30, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has announced the establishment of...

Company Deals

Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies

Fineline Cube Apr 30, 2025

Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a...

Company Drug

AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis

Fineline Cube Apr 30, 2025

US-based pharma giant AbbVie (NYSE: ABBV) announced regulatory approval from the US Food and Drug...

Company Drug

Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma

Fineline Cube Apr 30, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to...

Company Deals

Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems

Fineline Cube Apr 30, 2025

Itcure, a gene editing specialist based in Suzhou, has entered into a partnership with compatriot...

Company Deals

Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced a strategic partnership...

Company

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) released its Q1 2025...

Company Medical Device

Roche’s VENTANA TROP2 Device Receives FDA Breakthrough Designation

Fineline Cube Apr 30, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that its VENTANA TROP2 (EPR20043) RxDx...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-5635 in Chronic HBV

Fineline Cube Apr 30, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...

Company Deals

Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...

Legal / IP

BeiGene Wins USPTO Ruling Invalidating Pharmacyclics’ Patent Claims

Fineline Cube Apr 30, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company

AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines

Fineline Cube Apr 30, 2025

UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)...

Company

Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact

Fineline Cube Apr 30, 2025

US-based Pfizer Inc. (NYSE: PFE) released its Q1 2025 financial results, showing a -6% year-on-year...

Company

United Imaging Healthcare Reports 9.73% Revenue Decline in 2024 Financials

Fineline Cube Apr 29, 2025

China-based device giant United Imaging Healthcare (UIH, SHA: 688271) released its 2024 financial report, recording...

Company Deals

Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma

Fineline Cube Apr 29, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and...

Company Drug

Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial

Fineline Cube Apr 29, 2025

German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...

Company Drug

Kangpu Biopharmaceuticals Receives NMPA Approval for KPG-818 Phase IIb Study in SLE

Fineline Cube Apr 29, 2025

China-based Kangpu Biopharmaceuticals, Ltd announced that it has received approval from the National Medical Products...

Posts pagination

1 … 147 148 149 … 645

Recent updates

  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
  • Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
  • Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
  • Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Company Drug

Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.